Skip to content
Artwork for The Longevity Podcast: Alzheimer's and Brain Health Research
Health & FitnessMedicineScienceLife Sciences

The Longevity Podcast: Alzheimer's and Brain Health Research

Dung Trinh

AI-hosted deep dives into the latest Alzheimer's, dementia and brain health research, curated by Dr. Dung Trinh. Each episode breaks down a recent study or topic, such as diet, sleep, exercise, heart health, biomarkers, early detection and new treatments. We explain what the science says and what it may mean for staying sharp as we age.

Episodes are discussions generated with AI hosts. Every episode cites its sources so you can read the original research yourself. This podcast is for education only and is not medical advice. Talk with your doctor about your own health.

Play
  • 67 episodes
  • Avg 31 min
  • English
Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • June 16 · 21 min

    The Dementia Manual We Cannot Read

    Send us Fan Mail This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • June 15 · 20 min

    45% Of Dementia Risk Is Modifiable

    Send us Fan Mail What if the biggest lever for preventing dementia isn’t hidden in your DNA, but sitting in your calendar, your sleep, your diet, and even your hearing? We dig into a 2026 German study published in the Journal of Prevention of Alzheimer’s Disease that argues up to 45% of dementia risk is modifiable and then shows what “modifiable” actually looks like when you measure it person by person. We walk through how Brain Health Services flip the old model of waiting for symptoms into proactive brain health screening for people who feel fine today. The surprise is how many “worried well” participants still carried meaningful, fixable vulnerabilities: obesity, low Mediterranean diet adherence, poor subjective sleep quality, chronic stress, and hearing impairment. Using principal component analysis, the study groups real-world dementia risk factors into six practical clusters: psychosocial load, blood pressure, physical condition, hearing, lifestyle, and substance use. Then we connect those clusters to hard biology. We explain why hearing loss can raise cognitive load and push social isolation, why physical condition correlates with blood biomarkers like neurofilament light chain (NFL) and GFAP, and what those markers suggest about neurodegeneration and neuroinflammation. We also tackle the APOE4 question and the empowering takeaway that genetic predisposition does not erase the impact of fundamentals like sleep, exercise, diet, and stress skills. The most hopeful part: a single two-hour, hyperpersonalized assessment plus tailored counseling leads to reported lifestyle improvements for over 60% of respondents at six months. Listen, share this with someone who’s worried about cognitive decline, and leave us a review. Which one cluster would you “audit” first: sleep and stress, blood pressure, fitness, hearing, lifestyle, or substance use? This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • June 14 · 20 min

    What Happens When A Silent Disease Becomes Knowable

    Send us Fan Mail Alzheimer’s doesn’t wait for a diagnosis to begin. The brain changes can start quietly for years, even a decade, while someone looks totally fine, passes cognitive tests, drives, works, and pays the same routine healthcare bills as their peers. That raises a tough question with massive public health stakes: if the disease is already active, when does it start costing Medicare real money? We dig into a 2026 Journal of Prevention of Alzheimer’s Disease study that finally connects two missing halves of the puzzle: precise clinical trial data from cognitively normal adults with confirmed amyloid pathology, and real-world Medicare claims that record hospital stays, ER visits, home health care, and actual dollars spent. The surprising baseline finding is a true economic paradox: elevated amyloid alone does not meaningfully raise healthcare utilization or Medicare payments. The spending surge arrives later, when cognitive decline becomes disruptive enough to show up in claims and when frailty ramps up. The most important takeaway is what drives the spike. It is not primarily dementia-specific treatment. Costs jump because slipping executive function makes everyday chronic disease management fall apart, turning “cheap” conditions like hypertension or diabetes into emergencies like falls, injuries, surgeries, and long recovery stays. We also talk about the detection gap between sensitive research tools and rushed primary care, why cognitive reserve may delay the tipping point for highly educated cohorts, and the provocative next frontier: if blood tests like p-tau217 make preclinical Alzheimer’s visible to everyone, does knowledge alone change behavior and spending before symptoms begin? If this changed how you think about Alzheimer’s prevention, share it with someone who needs it, and subscribe, rate, and review so more people can find the show. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • June 11 · 20 min

    Why An Amyloid Positive Test Does Not Mean The Same Disease

    Send us Fan Mail A clean diagnosis feels like an X-ray: obvious problem, obvious fix. Alzheimer’s disease is the opposite, and the arrival of disease-modifying anti-amyloid therapies like lecanemab and donanemab makes that gap impossible to ignore. We dig into why real-world patients do not look like “pristine” clinical trial participants, and why a simple amyloid positive label can hide wildly different biology, risks, and likely outcomes. We explore what happens when amyloid burden is patchy or borderline, how centiloid scores and CSF biomarkers (especially the amyloid beta 42 to 40 ratio) create a probabilistic gray zone, and why cognitive decline often reflects more than plaques alone. Cerebrovascular disease and white matter injury can team up with modest amyloid to push a brain over the edge, which changes what “treating the cause” even means. Then we follow the fire inward to tau. Tau tangles disrupt neurons from the inside, and tau PET with Braak staging can reveal severe pathology even when someone still functions well, thanks to cognitive reserve. From there, we zoom out to the ATNIVS framework: Amyloid, Tau, Neurodegeneration, Inflammation, Vascular pathology, and Synuclein. We connect blood biomarkers like plasma NFL and GFAP to active neurodegeneration and neuroinflammation, and we explain why ARIA (amyloid-related imaging abnormalities) risk rises when fragile vessels, inflammation, and cerebral amyloid angiopathy collide with plaque-clearing antibodies. Finally, we cover a provocative twist: seed amplification assays detecting hidden alpha-synuclein in a meaningful share of patients diagnosed with Alzheimer’s, pointing to copathology that can change prognosis and potentially mask drug benefit. If you care about Alzheimer’s biomarkers, precision neurology, and the future of combination therapies, listen through to the end, then subscribe, share the episode, and leave a review with your biggest takeaway. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • June 10 · 21 min

    Creatine For The Brain

    Send us Fan Mail Your brain is an energy hog running on an ATP battery that lasts only seconds, and that one fact changes how you should think about “brain supplements.” We dig into why creatine is more than a weightlifting staple, how phosphocreatine works like a built-in power bank, and why the blood brain barrier makes brain saturation slow, picky, and easy to study the wrong way. If you’ve ever tried to boost focus and felt buried under wellness noise, this is the signal. We walk through the groups most likely to feel a real cognitive effect: vegans and vegetarians with lower dietary creatine exposure, older adults facing slower creatine synthesis and mitochondrial decline, and anyone under acute metabolic stress. The sleep deprivation trials are especially wild, showing that a high single dose during severe sleep loss can preserve ATP and reduce the cognitive crash, while still not replacing the deeper restorative work that sleep does. We also get honest about the clinical landscape: a small Alzheimer’s pilot shows a measurable brain-creatine increase and improved scores, while massive Parkinson’s and Huntington’s trials show no slowing of progression, pointing to the difference between metabolic failure and structural damage. Then we bring it back to practical guidance: why “creatinine” on a standard blood panel can mislead, why serum levels do not equal brain uptake, what dosing looks like in studies, how to pick creatine monohydrate with third-party testing, and which internet myths don’t hold up. If this helped you, subscribe, share it with a friend who’s running on fumes, and leave a review with your biggest creatine question. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • May 20 · 52 min

    The Glymphatic System And How Sleep Flushes Brain Waste

    Send us Fan Mail Sleep turns on a hidden plumbing system that pressure-washes the brain, clearing toxic waste that builds up during wakefulness. We connect brand-new human imaging with practical sleep habits so you can protect deep sleep, memory, and long-term cognitive health. • why the brain accumulates metabolic waste while awake • how the glymphatic system works and why science missed it for decades • the mouse discovery in 2012 and the 2024 human proof using gadolinium plus specialized MRI • perivascular spaces as the brain’s fluid highways • astrocytes, AQP4 water channels, and why deep sleep expands interstitial space • vasomotion as the mechanical pump and how slow wave brain activity controls it • amyloid beta and tau clearance plus the vicious cycle linking poor sleep and neurodegeneration • epidemiology on sleep duration, dementia risk, and why the curve is U-shaped • the medication paradox with sedatives like Ambien and why unconsciousness is not the same as restorative sleep • lifestyle levers: exercise, blood pressure control, side sleeping, alcohol timing, meal timing, and light exposure Take care of your brain, manage your blood pressure, and get a really good sideline night of sleep. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
  • May 20 · 19 min

    Why Gut Health Is An Ecosystem You Grow

    Send us Fan Mail A probiotic is supposed to help you recover after antibiotics. But what if the wrong probiotic acts like an invasive weed, moves into the empty real estate in your gut, and blocks your native microbiome from growing back? We unpack the science behind that unsettling possibility and use a comprehensive medical review by Dr. Kristen Glorioso to separate real microbiome research from gut health marketing that promises weight loss, brain fog cures, and “perfect” stool test scores. We walk through why the gut microbiome is an ecosystem, not an arcade game. Some of the most important organisms are strict anaerobes that cannot survive oxygen, so they are not something you can reliably buy in a capsule. We explore why microbes like Akkermansia muciniphila and Prevotella copri can be helpful in one context and harmful in another, and how competitive nutrient exclusion explains why diversity can be protective. Then we zoom out to the “for whom” problem: genetics, ancestry, and age can shift what a healthy baseline looks like, including research tying APOE4 to lower butyrate producing bacteria and downstream effects on inflammation and the blood brain barrier. From there, we get practical. We break down the post antibiotic study where a multi strain probiotic delayed recovery versus watchful waiting, why autologous fecal microbiota transplant can restore an ecosystem fast yet remains hard to implement, and what consistently works for most people: plant diversity like the 30 plants per week approach, whole foods that deliver fiber to the colon, live culture fermented foods, and aerobic exercise. We also clarify microbiome testing options, from 16S sequencing to shotgun metagenomics and metatranscriptomics, and how to use results to track change rather than chase a generic reference range. If you want a smarter, calmer way to think about gut health, hit play, then subscribe, share this with a friend who loves probiotics, and leave a review with your biggest takeaway or question. This podcast is created by Ai for educational and entertainment purposes only and does not constitute professional medical or health advice. Please talk to your healthcare team for medical advice. Never miss an episode—subscribe on your favorite podcast app!

    • Transcript
    • Chapters
Showing 61–67 of 67 episodes